Peripheral Blood <scp>CD4</scp> / <scp>CD8</scp> Ratio Predicts Out‐of‐Specification Products in Lisocabtagene Maraleucel Manufacturing
Our findings suggest that a low CD4/CD8 ratio (below one-third) may be a predictive marker for OOS outcomes, potentially supporting patient selection and treatment planning. Therefore, prospective validation using a larger cohort is warranted.
Authors
- Masao Matsuoka (ORCID: https://orcid.org/0000-0002-0473-754X)
- Jun‐ichirou Yasunaga (ORCID: https://orcid.org/0000-0002-7939-2080)
- Takahisa Nakamura (ORCID: https://orcid.org/0000-0003-4922-4569)
- Takafumi Shichijo (ORCID: https://orcid.org/0000-0002-1272-3738)
- Kisato Nosaka (ORCID: https://orcid.org/0000-0001-6682-2451)
- Koji Kato (ORCID: https://orcid.org/0000-0002-7397-1575)
- Hiro Tatetsu (ORCID: https://orcid.org/0000-0001-8131-3401)
- Taichi Hirano (ORCID: https://orcid.org/0000-0003-0055-4591)
- Mitsuhiro Uchiba (ORCID: https://orcid.org/0000-0003-3377-4216)
- Asami Yamada
- Shikiko Ueno
Institutions
- Kyushu University (JP)
- Kumamoto University Hospital (JP)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1002/cnr2.70413
- Primary Topic
- Facial Rejuvenation and Surgery Techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science